DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, for preeclampsia and acute ischemic stroke. The company also has an earlier-stage preclinical program, DM300, for severe acute pancreatitis, but its business is centered on advancing DM199 through clinical trials and regulatory review.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead recombinant KLK1 candidate being developed for preeclampsia and acute ischemic stroke.
Early-stage DM300 program targeting severe acute pancreatitis.
Customers
DiaMedica does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites, regulators, and potential development partners. If DM199 is approved, the end customers would be hospitals, physicians, and patients in maternal health and stroke care, with commercialization likely depending on a partner or licensing arrangement.
Run the preeclampsia and AIS studies and generate the data needed for regulatory advancement.
FDA and other agencies review pre-IND, IND, and clinical data before approval can progress.
May provide funding, development support, or commercialization rights for DM199.
Would use DM199 if approved for preeclampsia or acute ischemic stroke treatment.
Strategy
DiaMedica's strategy is to advance DM199 through clinical proof-of-concept and later-stage trials in preeclampsia and acute ischemic stroke. The company is also working to preserve flexibility through partnerships or licensing, since commercialization would require substantial capital and operational scale.
Preeclampsia is a new indication with potential clinical differentiation and value creation.
Stroke remains the core clinical program and a key path to eventual approval.
The company has no product revenue and depends on external capital to fund R&D.
If DM199 succeeds, the company may need a partner to support sales, manufacturing, and distribution.
Geography
The company is U.S.-based and its current business is primarily driven by clinical development and regulatory activity rather than product sales. Its ReMEDy2 stroke trial is described as global in scope, and the company is expanding its preeclampsia program through FDA interaction in the United States. Because it has no product revenue, geography mainly affects where trials are run, where regulators are engaged, and where future commercialization could occur.
Risks
DiaMedica is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, and financing dependence. Its lead asset must reproduce early signals in later studies, and the company may need to raise capital before any product revenue is available. Government agency staffing or funding disruptions could also slow FDA review and other approvals that the business depends on.
- Clinical trial failure or non-replication of dataImpact: HighLikelihood: Medium
DM199 must show consistent efficacy and safety in later trials to support approval.
Exposure: Preeclampsia and acute ischemic stroke programs
- Regulatory delay or adverse FDA feedbackImpact: HighLikelihood: Medium
The company depends on FDA review to advance from pre-IND/IND into later development.
Exposure: PE program and broader clinical timeline
- Financing and dilution riskImpact: High
The company has no product sales and relies on equity or other external funding.
Exposure: Operating runway and ownership dilution
- Government agency disruptionImpact: MediumLikelihood: Medium
Reduced staffing or funding at FDA/SEC can delay approvals and normal oversight functions.
Exposure: Regulatory process timing
- Commercialization execution riskImpact: Medium
If approved, DiaMedica may need partners or significant internal buildout for launch.
Exposure
Accounting
Judgemental itemsTrial expansion, manufacturing development, and clinical staffing directly affect operating loss.
Impact: Higher R&D spend can materially increase quarterly cash burn.
G&A includes non-cash share-based awards for executives and support staff.
Impact: Affects reported operating expense and dilution analysis.
Other income, net is driven mainly by interest earned on invested cash.
Impact: Changes in balances and rates affect non-operating results and liquidity.
Any upfront fees, milestones, or royalties would change the revenue profile materially.
Impact: Could introduce revenue recognition judgments once commercialization partnerships exist.
Similar listed companies
Publicly listed companies with a comparable business focus.
Silexion Therapeutics Corp
SLXNW · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Damora Therapeutics, Inc.
DMRA · Pharmaceutical Preparations
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
ProKidney Corp
PROK · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026